Browse articles from EyeWorld.org related to presbyopia. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Results from Phase 3 trials for non-infectious uveitis treatment ➤ FDA allows new gene therapy for Leber congenital amaurosis to begin clinical testing ➤ FDA approves OTC drop for redness ➤ Company news ➤ ASCRS news and events ➤ EyeWorld article of the week
➤ Presbyopia-correcting eye drop receives FDA approval ➤ Four-year, first-in-human results for IOL-based drug delivery system ➤ FDA approves new treatment for thyroid eye disease ➤ New registry establishes baseline for interventional glaucoma procedures in the U.S. ➤ Phase 3 study for DME does not meet primary endpoint, triggering strategic decisions ➤ Company news ➤ ASCRS news and events ➤ EyeWorld article of the week
When it comes to true presbyopia-correcting lenses, there are two main categories: extended depth of field and full depth of field. Both of these categories have new additions (at least new to the U.S. market), and surgeons already using these lenses are excited about the results.
➤ Launch of biosimilar for retinal disease ➤ New partnership to advance perimetry program ➤ Approval of thyroid eye disease treatment ➤ Collaboration to develop adjustable PCIOLs ➤ Progress in treatment for neuropathic corneal pain ➤ Priority review for thyroid eye disease treatment ➤ RMAT designation granted to investigational magnetic human corneal endothelial cell therapy ➤ Complimentary access to video journal ➤ ASCRS news and events ➤ EyeWorld article of the week
➤ 36-month results from first-in-human study with shape-changing IOL ➤ New data for recently approved EDOF IOL ➤ Company completes first-in-human robotic cataract surgery ➤ Phase 2 study approved for secondary IOL intended for low-vision patients ➤ Investigational device measures real-time intraoperative aqueous outflow ➤ FDA expands dosing on label for faricimab ➤ Company news ➤ ASCRS news and events
➤ First patients dosed in Phase 3 program evaluating sustained drug delivery for DME ➤ FDA accepts supplemental NDA for presbyopia treatment ➤ FDA grants IND to ocular inflammation, pain treatment for potential expanded indication ➤ Enrollment complete in Phase 3 trial evaluating retinitis pigmentosa therapy ➤ ASCRS news and events
➤ First patient treated with novel crosslinking approach for refractive error ➤ Multisociety working group established to set guidelines for modern IOL classification ➤ FDA reduces clinical trial requirement for new drugs to one pivotal trial ➤ ASCRS news and events
➤ New drop for temporary presbyopia relief approved ➤ First-in-human results for accommodating IOL ➤ Enrollment complete in Phase 2/3 trial for Stargardt therapy ➤ Type C meeting completed with FDA to advance urcosimod for neuropathic corneal pain ➤ Company news ➤ ASCRS news and events
➤ Study: low-dose pilocarpine reduces pupil diameter without significant ciliary muscle response ➤ First patient receives investigational surgical system for glaucoma ➤ Clinical program for RP gene therapy begins ➤ FDA approves IND for steroid-free, topical anti-inflammatory ➤ Compassionate use approved for investigational drug intended for neuropathic corneal pain ➤ Company news ➤ ASCRS news and events
➤ Study: ‘revolutionary,’ ‘world-first’ treatment for vision-threatening condition restores sight ➤ IDE granted to tissue-based presbyopia solution ➤ Fast Track designation granted for geographic atrophy treatment ➤ Phase 1 results for Stargardt gene therapy ➤ Topline Phase 1b results from study comparing a next-gen treatment to faricimab ➤ Enrolled patients complete dosing in part of trial evaluating X-linked retinoschisis therapy ➤ Company news ➤ ASCRS news and events
Get the latest ophthalmology news delivered to your inbox every Friday.